IGF1R and neoplasm: Additional IR/IGF1R tyrosine kinase inhibitors showing improved selectivity profiles have been developed, such as NVP-AEW541 developed by Novartis (2).90 This compound has cellular IC50 values of 0.086 μM and 2.3 μM for the IGF1R and IR respectively,90 and similarly reduced the growth of tumour xenografts in vivo.